First-of-Its-Kind HIV Vaccine Enters South African Human Trials Using Moderna’s Sequenced mRNA Technology

Tue, July 28 2026 /Mpelembe Media/ — Researchers at the La Jolla Institute for Immunology and Scripps Research have achieved a significant breakthrough by developing an HIV vaccine that successfully produced high levels of broadly neutralizing antibodies in primates. This innovative germline targeting approach functions as an “immune system bootcamp,” utilizing a sequence of specialized injections to train naive B cells to recognize and attack the virus’s most vulnerable regions. By mimicking the natural maturation of rare, effective antibodies, the vaccine overcomes HIV’s ability to mutate and hide behind glycan shields. Preclinical results showed that nearly half of the animal subjects developed the desired immune response, marking the most successful trial of its kind to date. Following these unprecedented results in non-human primates, scientists have transitioned to human clinical trials to evaluate the safety and efficacy of this multi-step immunization regimen. This collaborative effort represents a major advancement in the long-term mission to create a preventative vaccine for global public health. Continue reading →